Back to top
more

VYNE Therapeutics (VYNE)

(Delayed Data from NSDQ)

$2.50 USD

2.50
15,899

+0.03 (1.21%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.51 +0.01 (0.40%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VYNE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

VYNE Therapeutics Inc. [VYNE]

Reports for Purchase

Showing records 1 - 20 ( 32 total )

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/29/2024

Company Report

Pages: 7

2023 Results; Seeds Are Sown For BETi Pipeline''s Clinical Development; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

01/10/2024

Company Report

Pages: 6

Biomarker Results Reinforce VYN201''s MoA and Previous Positive Phase 1b Data; Phase 2b to Start in 2Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/13/2023

Company Report

Pages: 10

3Q23 Results; Buoyed by Positive Initial Data, BETi Pipeline Progresses Through Clinical Trials

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/10/2023

Company Report

Pages: 10

Fruits of Labor; KOL Event Spotlights VYNE''s Recent Clinical Development Progress

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

10/30/2023

Company Report

Pages: 7

Positive Early Vitiligo Clinical Data and VYN202 Profile Building; Target Reduced to $5.75 on Significant Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/14/2023

Company Report

Pages: 6

2023 Results; BETi Program Shows Signs of Blossoming; Topline Phase 1b Vitiligo Data in 3Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/12/2023

Company Report

Pages: 6

1Q23 Results; BETi Program Continues to Put Down Roots; VYN201 Phase 1b Data in 3Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/01/2023

Daily Note

Pages: 4

VYNE''s Latest Harvest: VYN202 Joins the InhiBET Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

04/19/2023

Company Report

Pages: 6

VYN201 Takes Root in Preclinical Model of IPF

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/30/2023

Company Report

Pages: 6

VYN201''s Safety Profile Matures on the Vine; Top-Line Phase 1b Vitiligo Data in Mid-23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/14/2023

Company Report

Pages: 6

Project Strong BETi Visibility This Year; Favorable Safety a Great Start; Split-Adjusted Target to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

01/10/2023

Daily Note

Pages: 4

VYN201 Continues to Bloom As First Vitiligo Patient Dosed in Phase 1a/b trial; Top-Line Data Expected 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/17/2022

Daily Note

Pages: 4

Start of Phase 1a/b Sows the Seeds for VYN201''s Future Clinical Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/11/2022

Company Report

Pages: 66

3Q22 Results; Ready, Set, Go!; VYN201 About to Initiate Phase1 Vitiligo Trial in the Coming Weeks

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 75.00

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/12/2022

Company Report

Pages: 6

2Q22 Results; BETi Program Readies For a Turn at Bat; Phase 1a/b in Vitiligo Slated to Begin in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

08/10/2022

Company Report

Pages: 6

FMX114 Misses in AD; Critical Shift Now to BETi Program; Target Reduced to $1.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

06/17/2022

Daily Note

Pages: 11

FMX114 Phase 2a Completes Enrollment Off of Positive Phase 1b Look; Top-Line Data Shortly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/18/2022

Company Report

Pages: 9

KOL Event Features InhiBET Platform; Vitiligo First Up For VYN201; FMX114 Phase 2a Data Shortly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/13/2022

Company Report

Pages: 6

1Q22 Results; Recent Clinical Progress Prepares the Ground for an Active Pipeline in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: VYNE Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

04/07/2022

Company Report

Pages: 8

FMX114 Starts to Bloom With Additional Positive Phase 1b Data; Phase 2a Results Expected in 2Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party